Patterns of use, clinical efficacy, safety and tolerability of ketamine and esketamine in treatment-resistant depression: towards registry-based surveillance systems.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of affective disorders"
DOI: 10.1016/j.jad.2021.10.036
Abstract: More data on the long-term effects of racemic ketamine and esketamine in TDR patients is needed. The implementation of centralized registries of their use for treatment of depression could be a tool of major importance… read more here.
Keywords: efficacy safety; surveillance systems; based surveillance; ketamine esketamine ... See more keywords
Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Real-World Setting Among Patients with Treatment Refractory Depression
Sign Up to like & getrecommendations! Published in 2022 at "CNS Spectrums"
DOI: 10.1017/s1092852922000293
Abstract: Abstract Background Ketamine, an N-methyl-d-aspartate receptor antagonist, has been “repurposed” as a rapid-acting antidepressant for treatment-resistant depression (TRD). The s-enantiomer of ketamine, “esketamine,” was FDA approved for TRD and depressive symptoms in adults with major… read more here.
Keywords: ketamine esketamine; ketamine; remission; intranasal esketamine ... See more keywords
Long-term safety of ketamine and esketamine in treatment of depression
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2022.2066651
Abstract: ABSTRACT Introduction Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019. Here we review what is known about the long-term safety… read more here.
Keywords: long term; safety; term safety; ketamine esketamine ... See more keywords